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Edited by Gianni CesareniAbstract Hypoxia-inducible factor 1 (HIF-1) is a master tran-
scription factor that mediates cellular and systemic homeostatic
responses to reduce O2 availability, such as erythropoiesis, angi-
ogenesis, and glycolysis. Using the yeast two-hybrid screening
system, we found that the oxygen dependent degradation
(ODD) domain of HIF-1a interacts with necdin, a growth sup-
pressor. The interaction of necdin with HIF-1a was conﬁrmed
using coimmunoprecipitation with the overexpressed HIF-1a.
Biological eﬀect of necdin on HIF-1a showed that necdin reduces
the transcriptional activity of HIF-1 under hypoxia. Moreover,
necdin decreased the level of the HIF-1a protein, but not that
of mRNA, implying a possibility of necdin-mediated HIF-1a
degradation. Furthermore, necdin has an anti-angiogenic activity
in the tube formation assay and CAM assay, which might be due
to the downregulation of HIF-1a. Collectively, these results sug-
gest that necdin can be a novel negative regulator of HIF-1a sta-
bility via the direct interaction.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Angiogenesis1. Introduction
Angiogenesis is required for invasive tumor growth and
metastasis and contributes to the control of cancer progres-
sion. Various angiogenesis inhibitors might be valuable for
cancer therapy [1,2]. As tumors increases in size and metastatic
potential and become neovascularized, ‘‘angiogenic switch’’
can be regulated by perturbing the local balance of pro-angio-
genic and anti-angiogenic factors [1]. Usually, tumors secrete
various angiogenic factors, including vascular endothelial
growth factor (VEGF) [3], allowing them to make the angio-
genic switch. Also, this switch can be regulated by environmen-
tal conditions such as local hypoxia, endogenous inhibitors,
and genetic backgrounds of the host. Especially, hypoxia is de-Abbreviations: HIF-1a, hypoxia-inducible factor-1a; ODD, oxygen-
dependent degradation; VEGF, vascular endothelial growth factor;
GFP, green ﬂuorescent protein; HEK 293 cells, human embryonic
kidney 293 cells; DMEM, Dulbeccos modiﬁed Eagles medium; CM,
conditioned media; PWS, Prader-Willi syndrome
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doi:10.1016/j.febslet.2005.05.072tected in central regions of solid tumors and plays an impor-
tant role in regulation on a variety of transcription factors
including the HIF [2,4].
HIF-1 is a master transcription factor regulated by oxygen
concentrations. [5–10]. HIF-1 is a heterodimer consisting of
hypoxia-inducible factor-1a (HIF-1a) and HIF-1b subunits.
To activate transcription of its target genes, HIF-1a dimerizes
with HIF-1b and then the dimmer binds to a hypoxia-response
element (HRE) [11]. Targets of HIF-1 include genes whose
protein products are involved in angiogenesis, energy metabo-
lism, erythropoiesis, cell proliferation and death, vascular
remodeling, and wound healing.
Under normoxia, HIF-1a is rapidly degraded by the ubiqui-
tin-proteasome pathway [7,12,13]. HIF-1a ubiquitination is
mediated by interaction with pVHL and p53 [14,15]. The asso-
ciation of HIF-1a with pVHL is accelerated by proline hydrox-
ylation in oxygen-dependent degradation (ODD) domain
region of HIF-1a [7]. This modiﬁcation is catalyzed by a spe-
ciﬁc family of enzymes termed HIF-1a proline hydroxylases
[7–9]. Recently, it was demonstrated that ARD1 acetylates
the Lys532 residue in the ODD domain of HIF-1a by transfer-
ring an acetyl group from Ac-CoA [16].
Under hypoxic conditions, HIF-1a is stabilized, which is
determined by balance between negative regulator such as
p53 and positive unknown factors, and accumulated in the nu-
cleus [17]. Stabilized HIF-1a exerts its transcriptional activity
by binding to the p300/CBP, SRC-1 (steroid receptor coactiva-
tor-1) family coactivators, and nuclear redox regulator Ref-1
[18,19]. p300/CBP, SRC-1, and Ref-1 synergistically enhance
HIF-1a-mediated transcriptional regulation under hypoxic
conditions. Therefore, the modulation of HIF-1a stability
and activation requires interaction of a variety of proteins with
HIF-1a.
In this study, we identiﬁed necdin (neurally diﬀerentiated
embryonal carcinoma-cell derived factor) as a novel protein
to interact with ODD domain of HIF-1a and control HIF-
1a stability and activity.2. Materials and methods
2.1. Reagents and antibodies
MG132 was from Calbiochem. Necdin antibody was kindly pro-
vided by Professor. Kazuaki Yoshikawa (Division of Regulation of
Macromolecular Functions, Osaka University). HIF-1a antibody
was kindly provided by Dr. J.W. Park (College of Medicine, Seoul
National University, Korea). Flag antibody was from Sigma.ation of European Biochemical Societies.
Fig. 2. Necdin decreases HIF-1a stability. (A) Upper, HEK293 cells
Fig. 1. Necdin interacts with HIF-1a in vivo. (A) HEK 293 cells were
transected with GFP-HIF-1a and/or Flag-necdin as indicated, and
then the cells were incubated at 1% O2 (hypoxia) for 4 h with/without
MG132. Total cell lysates were immunoprecipitated with anti-ﬂag
antibody. Immunoprecipitated materials were analyzed by western
blots with HIF-1a antibody. The presence of Flag-necdin/GFP-HIF-
1a or Flag-necdin was examined using anti-HIF-1a or anti-ﬂag
antibody. (B) HEK 293 cells were transected with GFP-HIF-1a and/
or Flag-necdin, and then the cells were incubated at 21% O2 with/
without MG132 treatment. Total cell lysates were immunoprecipi-
tated with anti-Flag antibody. Immunoprecipitated materials were
analyzed by western blots with HIF-1 antibody. The presence of
Flag-necdin/GFP-HIF-1a was examined using anti-ﬂag or anti-HIF-
1a antibody.
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For the yeast two-hybrid screening, we ampliﬁed the ODD domain
of HIF-1a by PCR and subcloned into the pGBT9. The full length of
necdin expression vector was constructed by PCR and subcloned into
pCMV-Tag (Stratagene). For HRE-luciferase assay, pBOS-hHIF-1a,
pBOS-hARNT, and pSV40pro-Epo-HRE-Luc vectors were kindly
provided by Dr. Fujii-Kuriyama (Tohoku University, Japan).
2.3. Two hybrid library screening and evaluation of protein-protein
interactions
Yeast strains, SFY526 and HF7c, obtained from CLONTECH were
used to assay protein–protein interactions and for library screening,
respectively. Two-hybrid assays using the GAL4 system were per-
formed according to the instructions of the manufacturer (CLON-
TECH).
2.4. Cell culture and hypoxic condition
Human embryonic kidney, HEK293, cells were maintained in Dul-
beccos modiﬁed Eagles medium (DMEM) supplemented with 10% fe-
tal bovine serum (Invitrogen). For hypoxic condition, cells were
incubated at 5% CO2 level with 1% O2 balanced with N2 in hypoxic
chamber (Forma).
2.5. Western analysis
Harvested cells were lysed in a lysis buﬀer [40 mM Tris–HCl (pH
7.4), 10 mM EDTA, 0.1% NP-40, 1 mM DTT and 120 mM NaCl]
and protein concentration was measured with BCA assay. Total cell
lysates were resolved in SDS–PAGE gels and detected with anti-HIF-
1a, anti-VEGF, anti-necdin, anti-a-tubulin antibodies. The bands
were visualized with the ECL Plus system (Amersham Pharmacia
Biotech).
2.6. Coimmunoprecipitation
After 24 h of transfection into HEK293 cells, cells were treated for
4–6 h under hypoxic/normoxic conditions before harvesting the cells.
Preparation of protein extracts immunoprecipitation, and western blot
were performed as described previously [16].
2.7. Transient transfections and luciferase assays
Five microgram of plasmids was transfected to HEK293 with
proper recombinations of eﬀector plasmids, using calcium phos-
phate-mediated methods. After transfection, cell lysates were ana-
lyzed for luciferase activity using an assay kit (Promega) and a
luminometer (Turner Design). Each extract was assayed three times,
and the mean relative light units were normalized by values obtained
from an extract prepared from empty vector-transfected cells. The
relative luciferase activity was calculated as relative light units/b-
galactosidase.
2.8. Tube formation assay
Each well of 48 well plate were coated with 150 ml/well of ice-cold
Matrigel, which were incubated 37 C for about 30 min. 5 · 104 HU-
VECs were seeded on each well and grown in the 500 ll conditioned
media (CM) with 10% FBS. After 16 h incubation, the cells were pho-
tographed.
2.9. CAM assay
Fertilized chicken eggs were incubated at 37 C. After 3.5 days, albu-
min was removed from the shell and then a window was cut from the
egg shell and covered with cellophane tape. Thermanox was loaded
with 2–4 ll of concentrated CM and air-dried. The eggs were incu-
bated until day 5, when the ﬁlms were applied to the CAM surface.
Angiogenesis assay was observed at 6.5–7 days.were transfected with Flag-necdin gene and then exposed to 1% O2
(hypoxia) for 6 h. HIF-1 protein expressions were examined by western
blot analysis. Lower, reverse transcriptase-PCR analysis was carried
out using speciﬁc primers for HIF-1a and b-actin. The relative protein
levels from three independent assays were quantiﬁed by densitometry.
B. HEK 293 cells were transfected with Flag-necdin and exposed to 1%
O2 for 5 h followed by the addition of 5 lM MG132 for 16 h as
indicated. HIF-1a protein expressions were examined by western blot
analysis.3. Results
3.1. Identiﬁcation and interaction of necdin with HIF-1a
We carried out the yeast two-hybrid assay to identify candi-
date proteins that interact with HIF-1a. The cDNA corre-
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1a was fused to the GAL4 DNA binding domain as a bait.
Using this bait, we screened mouse embryonic and T cell li-
brary as described previously [16]. After screening 6 · 106 yeast
transformants, 190 His+/Lac+ double-positive clones were iso-
lated from these transformants. The 64 clones were further se-
lected by b-galactosidase assays in another yeast strain, SFY
526, containing a GAL1UAS-lacZ reporter gene. DNA se-
quence and database searchers revealed that the nucleotide se-
quence of six clones encoded mouse necdin (M80840)+
(Genebank accession number).
To further conﬁrm the direct interaction of HIF-1a and nec-
din in vivo, we performed co-immunoprecipitation assays. The
necdin protein from total cell extracts immunoprecipitated the
HIF-1a protein under both hypoxic (Fig. 1A) and normoxic
conditions (Fig. 1B). Moreover, the interaction between
HIF-1a and necdin was enhanced in the presence of MG132,
a protease inhibitor (Fig. 1), suggesting a possibility that the
interaction of HIF-1a and necdin aﬀects the regulation of
HIF-1a stability.Fig. 3. Necdin reduces the HIF- 1a-mediated transactivation function and V
Epo-HRE-Luc (1 lg), pBOS-hHIF-1a (1 lg), pBOS-hARNT (0.1 lg) and Fla
O2 (normoxia) and then incubated at 21% O2 or 1% O2 for additional 24 h. Th
densitometry. (B) HEK 293 cells were transfected with Flag-necdin and then e
performed by western analysis. Lower, reverse transcriptase PCR analysis wa
VEGF expression from three independent assays were quantiﬁed by densito3.2. Downregulation of the protein stability of HIF-1a by necdin
To examine whether necdin is involved in the regulation of
HIF-1a protein expression, we exposed necdin overexpressing
HEK293 cells to hypoxia. Overexpression of necdin downreg-
ulated HIF-1a protein level, but it did not aﬀect mRNA levels,
suggesting that the decrease of HIF-1a levels by necdin is not
due to downregulation of its transcript (Fig. 2A), but to its
posttranslational regulation. Under normoxic conditions, the
protein levels of HIF-1a were also decreased by necdin (data
not shown). However, the HIF-1a protein was not decreased
even in necdin-transfected cells after MG 132 treatment (Fig.
2B). Therefore, these results indicate that necdin decreases
the HIF-1 protein by the reduction of protein stability of
HIF-1a, possibly via the proteosomal degradation pathway.
3.3. Necdin inhibits the transactivation activity mediated by
HIF-1
We examined whether necdin is involved in HIF-1 transcrip-
tional activity by using a luciferase reporter system, a pSV40
promoter-Epo-HRE-Luc reporter. The EpoHRE reporterEGF expression. (A) HEK 293 cells were transfected with pSV40pro-
g-necdin as indicated. Transfected cells were incubated for 24 h at 21%
e VEGF protein was measured in three independent assays followed by
xposed to 1% O2 for 16 h. Upper, VEGF and Flag-necdin (necdin) were
s carried out using speciﬁc primer for VEGF and b-actin. The relative
metry.
Fig. 4. Necdin has an anti-angiogenic activity in vitro and in vivo. (A) HEK 293T cells were transfected with Flag-necdin and changed with fresh
serum-free DMEM and conditioned media (CM) were collected for 24 h. HUVEC cells were seeded on Matrigel and after 16 h, necdin-mediated CM
was added. Treatment of CM collected from no vector (con), treatment of CM collected from empty vector transfected cells (mocka), or treatment of
CM collected from necdin transfected cells (necdin). (B) Concentrated CM (50–100·) were added to CAM surfaces of 4.5-day-old chick embryos and
after 1.5 days further incubation, the eggs were observed under a stereotype microscope (Leica). The eggs were treated with CM collected from no
vector (con), from empty vector transfected cells (mock), or from Flag-necdin transfected cells (necdin). (C) The inhibition rate was calculated from
three independent CAM asssays. Necdin has a signiﬁcant anti-angiogenic activity.
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normoxic and hypoxic conditions (Fig. 3A). Furthermore,
we investigated whether necdin modulates the HRE-contain-
ing gene, VEGF. As shown in Fig. 3B, the mRNA and protein
expression of VEGF were decreased in the presence of necdin
expression. Therefore, necdin attenuates the transcriptional
activity of HIF-1.
3.4. Necdin overexpression induces anti-angiogenic activity in
vitro and in vivo
Finally, to examine an anti-angiogenic activity of necdin, in
vitro tube formation assay was performed using human umbil-
ical vein endothelial cells (HUVECs) (Fig. 4A). Conditioned
media (CM) taken from necdin-transfected cells inhibited
markedly tube formation compared with the control and
mock. Next, in vivo CAM assay was also performed. As
shown in Fig. 4B, CM (50- or 200-fold concentration) taken
from necdin-transfected cells has a signiﬁcant anti-angiogenic
activity in in vivo CAM assay.4. Discussion
The regulation of HIF-1a stability and activity occurs at
multiple levels. Particularly modulations of HIF-1a protein
by interaction with other protein are critically important for
stabilization and activation of HIF-1a protein. In our eﬀortto further characterize HIF-1a protein function and regula-
tion, we identiﬁed an interaction between the ODD domain
of HIF-1a and necdin using the yeast two-hybrid system and
conﬁrmed this interaction in in vivo co-immunoprecipitation
assay.
Necdin, one of a cluster of genes in the neurodevelopmental
disorder Prader-Willi syndrome (PWS), was ﬁrst discovered as
a growth suppressor expressed predominantly in postmitotic
cells such as neuron and skeletal muscle and its expression sup-
presses the proliferation of several cells [20–22]. Moreover,
necdin is upregulated during neuronal diﬀerentiation and is
thought to play a role in cell cycle arrest in terminally diﬀeren-
tiated neurons [20,23]. Necdin has been described as a tran-
scriptional repressor to interact with and suppress functions
of various cytoplasmic and nuclear proteins such as E2F1,
p53, hnRNP U and NEFA [24–28].
In our study, we demonstrate that the interaction between
necdin and HIF-1a contributes to the downregulation of
HIF-1a protein level. Moreover, overexpressed necdin dimin-
ished HIF-1a protein stability and ﬁnally led to the decrease
in VEGF expression, due to decreasing the transcriptional
activity of HIF-1a. Furthermore, in vitro tube formation assay
and in vivo CAM assay demonstrate that necdin has an anti-
angiogenic activity. Herein, we suggest that necdin binds and
plays a role in HIF-1a stability negatively and ﬁnally enhances
the anti-angiogenic activity. Further studies remains to be
investigated the mechanism of this phenomenon.
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